Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
[Press Release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis